SCHEMBL19956946

SCHEMBL19956946

COc1cc2nccc(Oc3ccc(NC(=S)Nc4ccc(F)cc4)c(Cl)c3)c2cc1C(N)=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.66
PDGFRA P16234 8/20 0.66
KIT P10721 4/20 0.66
PDGFRB P09619 3/20 0.66
RET P07949 3/20 0.66
FGFR1 P11362 3/20 0.66
FLT1 P17948 3/20 0.66
FLT4 P35916 3/20 0.66
RIPK2 O43353 2/20 0.66
ABL1 P00519 2/20 0.66
ADORA3 P0DMS8 2/20 0.66
BCR P11274 2/20 0.66
TBXA2R P21731 2/20 0.66
FECH P22830 2/20 0.66
KIF5B P33176 2/20 0.66
DDR1 Q08345 2/20 0.66
MAP2K5 Q13163 2/20 0.66
PTK6 Q13882 2/20 0.66
CCDC6 Q16204 2/20 0.66
DDR2 Q16832 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19956937 0.92 KDR (0.64) KDRPDGFRAKITPDGFRBRET
SCHEMBL19956997 0.92 KDR (0.68) KDRPDGFRAKITPDGFRBRET
SCHEMBL1895176 0.92 KDR (0.72) KDRPDGFRAKITPDGFRBRET
SCHEMBL20927357 0.90 KDR (0.66) KDRPDGFRAKITPDGFRBRET
SCHEMBL19956923 0.89 KDR (0.62) KDRPDGFRAKITPDGFRBRET
SCHEMBL19956976 0.89 KDR (0.66) KDRPDGFRAKITPDGFRBRET
SCHEMBL19956985 0.88 KDR (0.72) KDRPDGFRAKITPDGFRBRET
SCHEMBL19956947 0.87 KDR (0.64) KDRPDGFRAKITPDGFRBRET
SCHEMBL19957067 0.87 KDR (0.75) KDRPDGFRAKITPDGFRBRET
SCHEMBL19957050 0.86 KDR (0.61) KDRPDGFRAKITPDGFRBRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KDR 150/4885PDGFRA 127/4885KIT 198/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KDR 150/4885PDGFRA 127/4885KIT 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.